DNA repair factor linked to breast cancer may also play a role in Alzheimer's disease
News Dec 01, 2015
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer's disease (AD). The results, published in Nature Communications, suggest that low levels of BRCA1 protein in the brain may contribute to dementia. The study was funded by the National Institutes of Health (NIH, USA).
"It's extremely interesting that one molecule can be critically involved in two apparently opposing conditions: cancer, in which too many cells are born and neurodegenerative disease, in which too many brain cells die off," said senior author Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease, San Francisco, and the Joseph B. Martin Distinguished Professor of Neuroscience, and professor of neurology at the University of California, San Francisco.
Mucke and colleagues suspected that defects in DNA repair mechanisms could contribute to cognitive decline in AD and focused their studies on BRCA1. BRCA1 plays a key role in repairing our genetic code and thus, is critical for cell survival.
When Mucke's group examined brains of patients who died with Alzheimer's, they discovered low levels of BRCA1. In addition, they found reductions of BRCA1 in the brains of mouse models of Alzheimer's. In fact, experimental reduction of BRCA1 levels in brains of healthy mice made their brain cells shrink and become dysfunctional.
The team also investigated the effects of BRCA1 on cognition. After researchers reduced BRCA1 levels in the brains of healthy mice, the animals developed problems with learning and memory. Mouse models of Alzheimer's showed even greater declines in learning and memory following reductions of BRCA1. In addition, lowering BRCA1 caused increased DNA damage in the brains of Alzheimer's mice.
One of the hallmarks of AD is accumulation of beta-amyloid protein fragments which are toxic and can lead to neuronal death. Mucke's team found that adding amyloid beta to neurons in a dish lowered levels of BRCA1.
According to the researchers, the findings suggest that accumulation of beta-amyloid lowers levels of BRCA1, which increases DNA damage in brain cells and may contribute to dementia.
"An emerging theme in neurodegeneration research is that normal DNA repair protects against damage that causes neurons to die in dementia and related disorders. This study supports and strengthens that theme by showing that beta-amyloid decreases the levels of the DNA repair gene BRCA1, and at the same time inhibits the ability to form new memories," said Roderick Corriveau, PhD, program director at NIH's National Institute of Neurological Disorders and Stroke, which provided funding for the study.
"The functions of BRCA1 in the brain remain to be fully elucidated," said Dr. Mucke, "but our findings suggest that it may play an important role in supporting critical brain functions in both health and disease."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Suberbielle E et al. DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nature Communications, Published November 30 2015. doi: 10.1038/ncomms9897
Availability of Brain Tumor Surgery Dye Increases for NHS PatientsNews
A chemical dye that lights up brain tumours during surgery should be available to more NHS patients in England, according to the National Institute for Health and Care and Excellence (NICE).READ MORE
The Puzzle of Axonal Geometry May Have Been Solved, Could Influence Machine LearningNews
Why are axons, the spindly arms extending from neurons that transmit information from neuron to neuron in the brain, designed the way they are?READ MORE
Autism Spectrum Disorder Linked to Shape of Brain's CerebellumNews
Structural differences in the cerebellum may be linked to some aspects of autism spectrum disorder, according to a neuroimaging study from Columbia University Irving Medical Center (CUIMC).